Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in Kunming, has entered into a licensing agreement with Chinese firm Kyinno Biotechnology. Through this agreement, Yunnan Baiyao secures the global research and development (R&D), manufacturing, and commercialization rights for Kyinno’s antibody drug, KA-1641. The agreement encompasses global territories.
KA-1641, currently in the pre-clinical stage of development, is primarily aimed at treating cancer cachexia. The financial terms of the deal include an upfront payment of RMB 6 million (USD 825,000), with potential further payments of up to RMB 32 million (USD 4.4 million) tied to R&D and regulatory milestones. Additionally, Yunnan Baiyao, Kyinno, and JOINN Laboratories’ subsidiary, JOINN Biologics—a Contract Development and Manufacturing Organization (CDMO) operating in the US and China—will engage in a tripartite agreement. JOINN Biologics will be responsible for the manufacturing and direct supply of KA-1641 as part of this agreement.- Flcube.com
